Ontology highlight
ABSTRACT:
SUBMITTER: Johansen P
PROVIDER: S-EPMC7089718 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Advances in therapy 20200211 3
<h4>Introduction</h4>Once-weekly semaglutide 1 mg is a novel glucagon-like peptide 1 receptor agonist (GLP-1 RA) that, in the SUSTAIN clinical trials, has demonstrated greater reductions in glycated haemoglobin (HbA1c) and body weight than the other GLP-1 RAs exenatide extended-release (ER) 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg. The aim of this analysis was to evaluate the relative cost of control of achieving treatment goals in people with type 2 diabetes (T2D) treated with once-weekl ...[more]